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Background: The study assessed birth trends per decade in offspring of females with inflammatory joint diseases
(IJD) compared with women without IJD.
Methods: This retrospective cohort study is based on data from the Medical Birth Registry of Norway from 1967 to
2009. We investigated singleton births in females with IJD (n = 7502) and compared with births from the general
population (n = 2 437 110). Four periods were examined: 1967–79, 1980–89, 1990–99 and 2000–09. In the logistic
regression analysis adjustments were made for maternal age at delivery and birth order. Odds ratios were obtained
for the associations between IJD and birth outcome for each period.
Results: Females with IJD had in average 65 deliveries / year (0.08 % of all births) in the 1970ies and 274 deliveries
/ year (0.5 % of all births) from 2000 to 2009. Adjusted Odds ratios (aOR) for newborns small for gestational age
were 1.5 (95 % CI 1.2, 1.9) in the earliest and 1.1 (95 % CI 0.9, 1.2) in the last period. Correspondingly, for birth
weight < 2500 grams aOR decreased from 1.4 (95 % CI 1.0, 1.9) to 1.1 (95 % CI 0.9, 1.4). For preterm birth aOR was 1.
1 (95 % CI 0.8, 1.5) in the first and 1.3 (95 % CI (1.1, 1.5) in the last period.
Conclusion: An increasing number of births among females with IJD were observed in the study period. Birth
weights of newborns of IJD women approached to birth weights in the general population, but preterm birth
remained a problem.
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Inflammatory joint diseases (IJD), here including rheuma-
toid arthritis (RA), spondylarthritis (SA), psoriatic arthritis
(PsA) and juvenile idiopathic arthritis (JIA) are charac-
terised by chronic, systemic inflammation and may also
affect internal organs. Previous studies have shown various
effects of IJD on birth outcome [1–4]. Especially, low birth-
weight in offspring and preterm birth have been identified
as prominent findings. Over time, improvements in diagno-
sis and treatment, and also change in registration of rou-
tines may influence birth outcomes [5, 6]. Before 1990
several females with IJD were dissuaded from having chil-
dren [7, 8], and there were little experience with monitoring
and medical treatment in pregnancy. In a study published* Correspondence: marianne.wallenius@ntnu.no
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nancy by health professionals, family or other patients [7].
Since the end of the 1990ies new treatment options like the
tumor necrosis factor (TNF)-α inhibitors have made more
women able to achieve remission and thus enabled them to
plan their pregnancies. Possible changes in pregnancy out-
comes along with improved treatment options have not
been published.
In the present study we wanted to assess secular
trends in the number of births and the effects of IJD on
preterm birth and birth weight in the newborns. The
data were provided by the Medical Birth Registry of
Norway from 1967 to 2009.Methods
Material
The Medical Birth Registry of Norway (MBRN) is a
population-based registry containing information on all
births in Norway since 1967 comprising more than 2.4le is distributed under the terms of the Creative Commons Attribution 4.0
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notification of every birth or late abortion from 12 com-
pleted weeks of gestation onwards. Since 2002 MBRN has
been organised under the Norwegian Institute of Public
Health. A standard antenatal notification form is filled in
at visits to a general practitioner, midwife or obstetrician
during pregnancy and is brought by the mother to the
place of birth. The midwife enters additional data re-
corded at the time of birth. Follow-up data are added to
the form until discharge of hospital births. The attending
midwife is responsible for the completion of the notifica-
tion form at the end of each birth. The form is co-signed
by the attending physician and sent to the MBRN within
one week after birth. In the period January 1st 1967 to
November 30th 1998 a notification form was used for all
live births and stillbirths after 16 weeks of gestation. From
December 1st 1998 a new and more comprehensive form
was used for all live births and stillbirths after 12 weeks of
gestation [9]. The new form intended to improve the reg-
istrations in MBRN and contains precoded fields for dis-
ease in mothers prior to pregnancy including rheumatoid
arthritis. In addition there are open text fields for maternal
diagnoses before and during pregnancy. The records in-
clude identification of the parents by their national identi-
fication numbers, demographic information of the
parents, maternal diagnoses before and during pregnancy,
parity, complications during pregnancy and delivery,
length of pregnancy, as well as information on the infant,
including birth weight, birth defects and other perinatal
problems. The variables have been decided by consensus
among obstetricians, neonatologists and epidemiologists.
Information about parity is available for the index preg-
nancy, but also from any previous registrations in MBRN.
In the present study we used the information from the
index pregnancy, but if this was lacking, we used informa-
tion based on previous registered pregnancies in MBRN.
Until December 1st 1998 diagnoses were recorded as
stated by the International Classification of Diseases
(ICD)-8 system. Afterwards the ICD-10 system has been
used. It provides differentiation of the various diagnoses of
IJD. Information on diagnoses was obtained from the pa-
tient’s doctor and from medical records. We have included
data from females with IJD who gave birth in the period
1967 – 2009. The diagnoses of IJD were based on free text
information in the birth registration form, as coded by
MBRN using the ICD-8 or ICD-10 system, respectively.
The study was performed in compliance with the
Helsinki Declaration and approved by the Regional Ethics
Committee of Central Norway (diary number 2011/127-3).
Exposure
We included anonymised cases with coding 712 in ICD-8,
comprising rheumatoid arthritis (RA), juvenile idiopathic
arthritis (JIA) psoriatic arthritis (PsA) and ankylosingspondylitis (AS). When the ICD-10 system was introduced
we used M05.0, M05.1, M05.8, M05.9, M06.0, M06.8,
M06.9 (RA), M45 (AS), M46.1 (spondylarthritis), L40.5
and M07.0, M07.1, M07.2 or M07.3 (PsA) and M08.0,
M08.1, M08.2, M08.3, M08.4, M08.8, M08.9 (JIA). The
different diagnoses within the IJD complex therefore had
to be analysed as a collected group to obtain a comparison
of the same diseases. We excluded unspecified arthritis,
inflammatory connective tissue diseases and vasculitis in
the selection of IJD patients (Additional file 1). All other
singleton deliveries in females without IJD 1967–2009
served as reference group.
Outcomes
Parity was defined as the total number of previous preg-
nancies registered per birth including spontaneous abor-
tions after gestational week 16, live births and stillbirths.
We also studied mean birth weight (BW) for the new-
born, the proportion of newborns with BW < 2500 gram
and the proportion born small for gestational age (SGA).
SGA was defined as BW < 10 percentile for expected
BW for gestational age. Gestational age at birth was
based on ultrasound before 20 weeks or computed by
the last menstrual period. Birth before 37 + 0 gestational
weeks was defined as preterm.
Statistical analysis
Births for females with IJD and reference deliveries were
stratified into four periods: 1967–79, 1980–89, 1990–99
and 2000–09. Comparison of groups was studied by Stu-
dent’s t-test for continuous variables and chi-square tests
for categorical variables. Logistic regression analysis was
used to assess associations between IJD and perinatal
outcomes. We adjusted for parity and maternal age at
delivery. Multivariable linear regression analysis was
used to analyse mean differences in BW of the newborns
of mothers with IJD and reference women. The explana-
tory variables were maternal age at delivery, gestational
age, gender of infant and parity [10, 11]. Values of p that
were <0.05 were considered significant. Data were ana-
lysed using the Statistical Package of Social Sciences,
version 19.0 (SPSS Inc., Chicago, Illinois, USA) and Sta-
tistics / Data Analysis (STATA) version 12.1 (Stata Corp,
Lakeway Drive College Station, Texas, USA).
Results
From 1967 to 2009 a total of 7502 births were regis-
tered in females with IJD forming 0.3 % of totally 2.4
million births in Norway in the period. In the earliest
period, 1967–1979, the births in females with IJD
constituted 0.08 % of all births. This increased to
0.5 % in 2000–2009. Correspondingly, in average 65
deliveries annually were registered in females with IJD
during 1967–1979, increasing to 274 each year after
Wallenius et al. BMC Pregnancy and Childbirth  (2016) 16:123 Page 3 of 6year 2000. In 2000–2009 (n = 2736 births) when de-
tailed IJD diagnoses were available through ICD-10,
the distribution of diagnoses was: RA 51 %, SA 32 %,
PsA 10 % and JIA
7 %. The mean age at delivery for females with IJD
was higher than among the reference women through all
periods, and parity was higher from 1990 onwards. In
the period 2000–2009 more females with IJD were
smoking at time of conception than among the refer-
ences (Table 1). For offspring of IJD mothers the crude
mean birth weight (BW) was significantly lower than in
controls through all periods. However, the mean BW dif-
ference decreased from −61 g in the 1970ies to −17 g
after year 2000, and was no longer significant for the last
period (Table 2). The risk of BW < 2500 g was signifi-
cantly higher in newborns of IJD women from 1980 to
1999 with an aOR varying from 1.4 (95 % confidence
interval (CI) 1.2, 1.8) to 1.2 (95%CI 1.03, 1.5), but not
from year 2000 (aOR 1.2 (95 % CI 0.9, 1.4)). Similarly,
the risk of SGA births was higher for mothers with IJD
from 1967 to 1999, and the aOR varied from 1.5 (95 %
CI 1.2, 1.9) to 1.2 (95 % CI 1.1, 1.4). After year 2000 the
risk of SGA was not significantly different between IJD
females and references (aOR 1.1 (95%CI 0.9, 1.2)). How-
ever, the risk of prematurity was significantly higher
among offspring of IJD mothers from 1980 onwards
(Table 3). The risk varied from 1.5 (95 % CI 1.2, 1.8) in
the 1980ies to 1.3 (95 % CI 1.1, 1.5) from year 2000.
Discussion
Since 1967 births among females with IJD have signifi-
cantly increased. The low number of births during the
earliest period may have several explanations. In accord-
ance with previous reports females with IJD may haveTable 1 Maternal age, parity and smoking habits in births of female
year of delivery, Norway 1967-2009













645 0.08 28.2 (5.6)





1613 0.3 28.3 (5.1)
References 517621 27.3 (5.0)
1990-1999 IJD
women
2508 0.4 29.7 (5.2)





2736 0.5 31.1 (5.1)
References 564299 30.0 (5.1)
IJD inflammatory joint disease, SD standard deviation, n.a. not applicablebeen advised not to have children [7, 8]. After 1990 new
treatments have evolved and knowledge has been gath-
ered about the use of anti-inflammatory drugs before
and during pregnancy. Thus more women with inflam-
matory active disease have been able to plan pregnancy.
Biological agents like the TNF-α inhibitors, that target
cytokines and immune cells, were introduced in Norway
in 1999. TNF-α inhibitors are effective inhibitors of dis-
ease activity and are now recommended used until
conception [12]. High inflammatory disease activity has
a negative effect on sexual function [13], and better
treatment options may also improve the sexual function
and the possibility to achieve pregnancy. Risk of devel-
oping IJD increases with age, and the age of primiparous
Norwegian women has increased since 1967 and is cur-
rently 28.5 years [14]. Thus, the higher proportion of
births in females with IJD may be caused by the general
increase in maternal age as well as improved docu-
mented safety of medical treatments.
We observed that the mean BW in newborns of IJD
women approached that of the reference women during
the study period, and the mean difference was no longer
statistically significant after year 2000. The proportion of
newborns with BW <2500 grams declined from 6 % dur-
ing 1967 – 1979 to 4 % after year 2000 in females with
IJD. Correspondingly, the SGA proportion declined from
17 % to 8 %. Interestingly, these declines coincide with
the introduction of better treatment options. Low BW
has been associated with high disease activity at concep-
tion and during pregnancy [1, 2]. TNF-α inhibitors may
be administrated up to time of conception [15, 16] and
may help more women with inflammatory active IJD to
stay in or close to remission until they conceive. Better
knowledge of the use of other anti-inflammatory drugss with IJD and reference births from the general population by
elivery p-value Parity mean
(SD)
p-value Smoking at time of
conception (%)
p-value
<0.001 1.0 (1.1) 0.6 n.a.
1.0 (1.1) n.a.
<0.001 0.8 (0.9) 0.2 n.a.
0.9 (1.0) n.a.
<0.001 1.0 (1.1) 0.007 n.a.
0.9 (1.0) n.a.
<0.001 1.0 (1.1) <0.001 22.9 p < 0.0001
0.9 (1.0) 19.4




Group Total n Birth weight* (gram) mean (SD) p-value * Mean difference in birth weight**(gram) mean (SD) 95 % CI p-value**
1967-1979 IJD 645 3404.7 (626.1) <0.001 −61.2 (19.7) −99.9, −22.5 0.002
Ref 773563 3486.9 (585.3)
1980-1989 IJD 1613 3428.9 (634.5) <0.001 −43.6 (12.6) −68.3, −18.7 0.001
Ref 517621 3512.9 (584.5)
1990-1999 IJD 2508 3477.2 (626.5) <0.001 −48.5 (10.3) −68.7, −28.3 <0.001
Ref 581627 3552.5 (600.3)
2000-2009 IJD 2736 3500.8 (590.0) <0.001 −16.8 (8.7) −33.8, 0.1 0.05
Ref 564299 3551.0 (590.9)
*t-test **Multiple linear regression analysis with covariates for gestational age, maternal age at delivery, gender and parity
IJD inflammatory joint diseases, Ref references, SGA small for gestational age, OR odds ratio, CI confidence interval
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and sulfasalazine may also have influenced the results
[16, 17]. For females with IJD Norwegian national guide-
lines suggest regularly surveillance in pregnancy from
general practitioners, rheumatologists, obstetricians and
other specialists when necessary [18]. The improved care
taking and monitoring of pregnant women with IJD may
have influenced our results. Ultrasound surveillance of
fetal growth has become more widespread over the study
period, and the use of ultrasound to detect intrauterine
growth restriction may have had an impact on low BW
and SGA. The proportion of preterm deliveries from
1979 onwards was 7 % in IJD women compared to
around 5 % in reference women. Thus, the observed dif-
ference in preterm birth has persisted over the years des-
pite the introduction of new effective drugs. In the
earliest period (1967–1979) the number of cases was in-
sufficient for interpretation. In a Danish population
based study spanning from 1977 to 2008, offspring of fe-
males with RA had a 1.5 higher risk of preterm birth
than in the general population [19]. The study did not
examine secular trends. The newborns of RA womenTable 3 Newborns with birth weight < 2500 grams, SGA and preter
with reference births from the general population by year of birth, N
Period of
birth
Group Total n Birth weight < 2500 gram SGA
n % ORa 95 % CI p-value n
1967-1979 IJD 645 37 5.7 1.4 1.0, 1.9 0.07 109
Ref 773563 32962 4.3 91 495
1980-1989 IJD 1613 91 5.6 1.4 1.2, 1.8 0.001 201
Ref 517621 20250 3.9 54 770
1990-1999 IJD 2508 119 4.7 1.2 1.03, 1.5 0.03 267
Ref 581627 22541 3.9 51 705
2000-2009 IJD 2736 117 4.3 1.2 0.9, 1.4 0.12 210
Ref 564299 20907 3.7 41 094
IJD inflammatory joint diseases, Ref references, SGA small for gestational age, OR od
aAdjusted for maternal age at delivery and parityalso had a slightly lower BW [19]. The observed in-
creased risk of preterm birth was present both in females
diagnosed with RA and in those with preclinical RA.
The latter group had not been exposed to any anti-
rheumatic medication. The study hypothesized that po-
tential disease-induced factors influenced the observed
differences in fetal growth and preterm birth. These fac-
tors are still unknown. A higher rate of preterm birth
was also reported in another study of females with RA
spanning from 2001 to 2009. Among 46 pregnancies
28 % delivered prior to 37 weeks [20]. The study did not
find any associations between preterm birth and active
disease at conception or during pregnancy. However,
discontinuation of medication because of pregnancy was
associated with a significantly earlier gestational age at
delivery. We did not have information about drug expos-
ure in pregnancy, and isolating the effect of disease ver-
sus treatment is difficult in our material. A few studies
have indicated that use of prednisone, even in low dose
may induce preterm delivery [2, 21]. Prednisone has
been one of the most frequently used medications to
treat inflammation in pregnant arthritic females duringm delivery in females with inflammatory joint diseases compared
orway 1967-2009
Preterm birth
% ORa 95 % CI p-value n % ORa 95 % CI p-value
16.9 1.5 1.2, 1.9 <0.001 37 5.7 1.1 0.8, 1.5 0.53
11.8 40 475 5.2
12.4 1.2 1.04, 1.40 0.01 117 7.2 1.5 1.2, 1.8 <0.001
10.6 25 354 4.9
10.6 1.2 1.1, 1.4 0.001 180 7.2 1.4 1.2, 1.6 <0.001
8.9 30 635 5.3
7.7 1.1 0.9, 1.2 0.31 195 7.1 1.3 1.1, 1.5 0.001
7.3 31 552 5.6
ds ratio, CI confidence interval
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early seventies when the use of prednisone was sparsely
documented in pregnancy [22–25]. More women with
IJD were smoking at time of conception during 2000–
2009, but we did not have information about smoking
before year 2000. Thus, it is unknown how smoking
might have influenced the results overall.
An advantage of the present study was the availability
of population based data from a national registry. This
limits selection bias of IJD cases and ensures representa-
tive references.
Among potential limitations we cannot exclude the
possibility of misclassification bias. However, a validation
study of a selection of rheumatic diagnoses in MBRN in-
cluding inflammatory arthritic diagnoses, reported that
97 % of the diagnoses were correct [26]. We excluded
unspecified arthritic diseases, inflammatory connective
tissue diseases and vasculitis in the selection of IJD cases
(Additional file 1). The birth outcomes of mothers with
specific IJD diagnoses were not possible to study separ-
ately. During the period with ICD-8 coding, all IJD dis-
eases were grouped together, and the number of cases in
each diagnostic group of ICD-10 coding was not large
enough. Another possible limitation is underreporting of
diagnoses. MBRN has validated 169 females with rheum-
atic diagnoses in the period 1967–1995. Overall, 10 % of
pre-pregnant diagnoses were underreported. However,
underreporting was most pronounced during the earliest
period (1967–1976) when it was 45 % [26]. Underreport-
ing may certainly have led to an underestimate of births
in IJD women especially during the earliest study dec-
ade. Finally, we lacked detailed information such as so-
cioeconomic status and clinical data regarding body
mass index, disease activity and medication in preg-
nancy. Information about smoking habits was only avail-
able after 1999.
Conclusion
An increasing number of births among females with in-
flammatory joint disease have been observed between
1967 and 1999. Birth weight was lower in newborns of
mothers with inflammatory joint disease than in the gen-
eral population until 1999, but not later. However, an in-
creased preterm birth rate seems to persist.
Additional file
Additional file 1: Appendix with excluded codes in the patient and
reference populations, according to the ICD-8 and ICD-10 systems.
(DOC 24 kb)
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